Showing 2661-2670 of 3039 results for "".
- Azura Ophthalmics Raises $20 Million for Registration Studies for Treatment of Meibomian Gland Dysfunctionhttps://modernod.com/news/azura-ophthalmics-raises-20-million-for-registration-studies-for-treatment-of-meibomian-gland-dysfunction/2478445/Azura Ophthalmics announced a $20 million financing to advance Azura’s lead product candidate AZR-MD-001 through a registration study for the treatment of meibomian gland dysfunction (MGD). Azura’s novel medicines in development are designed to address abnormal hyperkeratinization – the bu
- Concerns Over Surgical Waste Are Clouding Future of Single-Use Device Markethttps://modernod.com/news/concerns-over-surgical-waste-are-clouding-future-of-single-use-device-market/2478423/The global single-use surgical device market has shown steady growth over several decades, reaching a peak of $3.4 billion in 2019, but growing concerns over the amount of waste created by disposable surgical devices have raised questions about future growth prospects, according to a Market Scope
- Bausch Health and BHVI Announce Global Licensing Agreement For Myopia Control Contact Lenshttps://modernod.com/news/bausch-health-and-bhvi-announce-exclusive-global-licensing-agreement-for-myopia-control-contact-lens/2478422/Bausch Health has acquired an exclusive license for a myopia control contact lens design developed by BHVI, an Australian not-for-profit organization with an international focus on vision research. Terms of the deal were not disclosed. Bausch + Lomb will pair BHVI’s novel cont
- BVI Acquires Benz Research & Development, Strengthening IOL Design, Production and Sales Capabilitieshttps://modernod.com/news/bvi-acquires-benz-research-development-strengthening-iol-design-production-and-sales-capabilities/2478419/BVI announced its recent completion of the acquisition of Benz Research & Development and its customized contact lens subsidiary, SpecialEyes, both based in Sarasota, Florida. Terms of the deal were not disclosed. The Benz portfolio of performanc
- Outlook Therapeutics Announces Initiation of Open-Label Safety Study of Lytenava for Wet AMDhttps://modernod.com/news/outlook-therapeutics-announces-initiation-of-open-label-safety-study-for-lytenava-for-wet-amd/2478410/Outlook Therapeutics announced the initiation and enrollment of the first patients in its planned supplemental open-label safety study evaluating ONS-5010/Lytenava (bevacizumab-vikg) for the treatment of wet age-related macular degeneration (AMD) (NORSE THREE). The open-label safety study
- J&J Pauses COVID-19 Vaccine Studies After “Unexplained Illness”https://modernod.com/news/jj-pauses-covid-19-vaccine-studies-after-unexplained-illness/2478407/Johnson & Johnson confirmed that it paused further dosing in all clinical studies of its COVID-19 vaccine candidate JNJ-78436735, including the phase 3 ENSEMBLE trial, due to an “unexplained illness” in a participant. The company noted that the subject’s illness is being rev
- EyeCare4Kids Partners with 1-800 Contacts to Launch Sight the Worldhttps://modernod.com/news/eyecare4kids-partners-with-1-800-contacts-to-launch-sight-the-world/2478400/1-800 Contacts and nonprofit EyeCare4Kids announced the launch of Sight the World, which will utilize innovative vision care technology from 1-800 Contacts to provide free glasses and contact lenses for underserved adults and children globally. The announcement comes on World Sight Day, an intern
- Alcon Celebrates World Sight Day 2020 and Continues Commitment to Improving Worldwide Access to Eye Carehttps://modernod.com/news/alcon-celebrates-world-sight-day-2020-and-continues-commitment-to-improving-worldwide-access-to-eye-care/2478392/Alcon celebrates World Sight Day through its corporate giving and company-led initiatives focused on improving access to quality eye care. In the spirit of this year’s theme, “Hope in Sight,” Alcon associates will help spark donations to global nonprofit organizations that advance eye health. The
- Tarsus Releases Data from Io and Europa Trials for TP-03 to Treat Demodex Blepharitis and Begins Phase 2b/3 Saturn-1 Trialhttps://modernod.com/news/tarsus-releases-data-from-io-and-europa-trials-for-tp-03-to-treat-demodex-blepharitis-and-begins-phase-2b-3-saturn-1-trial/2478374/Tarsus Pharmaceuticals announced data from its phase 2 trials, Io (a Phase 2a, single-arm open-label trial) and Europa (a Phase 2b, randomized vehicle-controlled trial), evaluating the safety and efficacy of TP-03, a novel ophthalmic therapeutic being developed for t
- Tarsius Pharma Achieves Positive Results in Proof of Concept Study for TRS01 Targeting Uveitishttps://modernod.com/news/tarsius-pharma-achieves-positive-results-in-proof-of-concept-study-for-trs01-targeting-uveitis/2478367/Tarsius Pharma announced that the GADOT 20/20 trial of its novel TRS01 drug for treating active anterior noninfectious uveitis, demonstrated significant improvement in critical measures such as Anterior Chamber Cells, pain reduction and increased visual acuity. The GADOT 20/20 trial was a